A Double-Blind, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795
Latest Information Update: 15 May 2026
At a glance
- Drugs ARO PNPLA3 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
Most Recent Events
- 05 May 2026 According to Janssen Pharmaceuticals media release, Data from this study, published in The New England Journal of Medicine.
- 05 May 2026 Results published in the Media Release
- 16 Aug 2023 Status changed from recruiting to completed.